How to Compare UK Weight Loss Providers: A Clinical Guide

Comparing UK weight loss providers is not straightforward when every service claims to be safe, effective and clinically led. The differences that matter most are rarely visible in a headline price or a list of available medicines. This article explains what genuinely separates one provider from another, which regulators to check, how to verify that clinical oversight is real rather than cosmetic, and what a proper weight management assessment should include. Whether you are considering semaglutide, tirzepatide or a non-pharmacological programme, understanding these distinctions will help you make a safer, better-informed choice.

What actually differs between UK weight loss services?

UK weight loss services differ most meaningfully in the depth of clinical oversight provided, including assessment thoroughness, monitoring frequency, lifestyle support and escalation pathways, rather than simply which medicines they offer.

UK weight loss services differ most meaningfully in the depth of clinical oversight they provide, not simply in which medicines or programmes they offer. Some services are built around a structured, ongoing relationship with a prescriber and a pharmacist, while others function primarily as a one-time consultation followed by a prescription, with little or no follow-up. That distinction matters because weight management is a long-term condition, and the evidence base for pharmacological treatment assumes continued monitoring and support, as reflected in NICE guidance on obesity (NG238) and the relevant NICE technology appraisals for semaglutide and tirzepatide.^[1]

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, and medicines are only prescribed where clinically appropriate after individual assessment.

Beyond clinical oversight, services also differ in:

• Assessment thoroughness: whether they take a full medical history, review current medications and check for contraindications before prescribing

• Monitoring frequency: how often a prescriber or pharmacist reviews progress, side effects and dose changes

• Lifestyle support: whether behavioural, dietary or physical activity guidance is integrated or entirely absent

• Escalation pathways: whether there is a clear route back to a clinician if something goes wrong

A service that offers only a brief questionnaire and rapid dispatch is structurally different from one that includes a named prescriber, documented clinical reasoning and scheduled reviews. When comparing providers, these structural differences are more informative than price or speed of delivery alone.

Which regulators should a legitimate UK provider be registered with?

Legitimate UK online pharmacies must be registered with the GPhC (Great Britain) or PSNI (Northern Ireland), with prescribers verifiable on the GMC, NMC or GPhC register; clinic-based services are regulated by the CQC, HIS, HIW or RQIA depending on nation.

A legitimate UK online weight management provider should be registered with the appropriate pharmacy regulator if it operates as an online pharmacy. In Great Britain (England, Scotland and Wales), that regulator is the General Pharmaceutical Council (GPhC); in Northern Ireland, it is the Pharmaceutical Society of Northern Ireland (PSNI). GPhC and PSNI are separate registers: a provider registered with one is not automatically registered with the other. Any prescribers working within a service must be registered with the General Medical Council (GMC), the Nursing and Midwifery Council (NMC) or the GPhC, depending on their professional role. These registrations are legal requirements, and you can verify each one directly on the relevant regulator's public register.

For services operating as clinics rather than pharmacies, the relevant regulator depends on the nation: the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, Healthcare Inspectorate Wales (HIW) in Wales, and the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland. A provider that is neither registered with the appropriate pharmacy regulator nor the relevant clinic regulator, and is offering prescription medicines, is operating outside the regulatory framework that protects patients.

When checking a provider, look for:

• GPhC or PSNI registration: searchable at pharmacyregulation.org (GPhC) or psni.org.uk (PSNI); the provider's registration number should be displayed on its website

• Named superintendent pharmacist: GPhC-registered online pharmacies are required to have one, and their name should be findable on the register

• Prescriber registration: individual prescribers should be verifiable on the GMC, NMC or GPhC register by name

• CQC, HIS, HIW or RQIA registration (where applicable): searchable on each regulator's own website

Note that the GPhC internet pharmacy logo scheme closed to new applications in June 2025 and was formally retired on 31 December 2025, so the absence of that logo is no longer a meaningful signal either way. Rely on the live registers rather than any logo displayed on a website.

Does the price difference between providers reflect a difference in care?

A significantly lower price can indicate that assessment or monitoring steps have been removed; the most useful comparison is the total cost of a service that includes safe, monitored, ongoing care using a licensed UK medicine.

A higher price does not automatically indicate better clinical care, but a significantly lower price can sometimes suggest that elements of the assessment or monitoring process have been reduced. The cost of a weight management service reflects several components: the medicine itself, the prescriber's time, pharmacist oversight, dispensing and delivery, and any ongoing support or review appointments. When a price appears unusually low, it is worth asking which of those components has been removed.

Medicines used in weight management include semaglutide (available as Wegovy, which is MHRA-authorised for chronic weight management, and separately as Ozempic, which is licensed for type 2 diabetes and is not licensed for weight management in the UK) and tirzepatide (Mounjaro, which is MHRA-authorised both for type 2 diabetes and for chronic weight management).^[4][9] Each has a wholesale cost that sets a practical floor on what a legitimate service can charge for the licensed UK product. A price that falls well below that floor should prompt questions about the product's provenance and whether it is genuinely the licensed UK medicine.

When comparing costs, consider:

• What the consultation fee covers: is it a one-off charge or does it include follow-up reviews?

• Whether monitoring is included: some services charge separately for dose-change reviews or safety checks

• What happens if you need to pause or stop: are there exit costs or minimum commitment periods?

• Whether the medicine is the licensed UK product: unlicensed or compounded versions carry different risk and regulatory profiles

The most useful comparison is not the headline price but the total cost of a service that includes safe, monitored, ongoing care.

How do you check whether a provider's clinical oversight is genuine?

Genuine oversight is confirmed by a named, verifiable prescriber, a documented monitoring process, access to a pharmacist, a clear complaints pathway, and publicly available inspection reports from the GPhC, CQC or equivalent regulator.

Genuine clinical oversight is identifiable by specific, verifiable features rather than reassuring language on a website. A provider with real oversight will have a named, registered prescriber who reviews each patient's case individually, a documented process for monitoring response and side effects, and a clear pathway for a patient to speak to a clinician if a problem arises between scheduled reviews.

Practical checks you can carry out before committing to a service include:

• Ask for the prescriber's name and registration number and verify it on the GMC, NMC or GPhC register. A legitimate service will provide this without hesitation.

• Ask how dose changes are managed: is there a clinical review before each escalation, or is it automated?

• Check whether there is a pharmacist available for queries: GPhC-registered pharmacies are required to have a superintendent pharmacist, and that person should be contactable.

• Look at the complaints and escalation process: a provider should be able to tell you clearly what to do if you experience a side effect or have a concern.

• Check inspection reports: GPhC and CQC publish inspection findings publicly for services they regulate; HIS, HIW and RQIA do likewise for services in Scotland, Wales and Northern Ireland respectively. These give an independent view of how a service operates in practice.

Be cautious of services where the only point of contact is a chatbot or a generic email address, where there is no named clinician, or where the assessment consists solely of a short tick-box questionnaire with no opportunity for a clinician to ask follow-up questions. These are structural indicators that oversight may be limited rather than genuine.

If you experience a suspected side effect from a weight management medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.^[10][11]mhra.gov.uk.

What should a proper weight management assessment include?

A proper assessment must cover full medical history, current medicines, contraindications, BMI, weight-related comorbidities, lifestyle and psychological factors before any prescribing decision, in line with NICE guidance NG238.

A proper weight management assessment should establish a patient's full medical history, current medicines, relevant comorbidities and individual risk factors before any treatment decision is made. This is not a formality: it is the clinical basis on which a prescriber determines whether a pharmacological or non-pharmacological approach is appropriate, which medicine (if any) is suitable, and at what starting point.

NICE guidance on obesity (NG238) and the related technology appraisals for semaglutide (Wegovy) and tirzepatide (Mounjaro) set out the clinical context within which weight management interventions should be considered, including the role of BMI, waist circumference and the presence of weight-related comorbidities in determining eligibility and priority. A service that does not gather this information cannot be making a genuinely individualised clinical decision.

A thorough assessment should cover:

• Weight history and previous attempts at management: including what has and has not worked

• Current medicines: some interact with weight management treatments or affect eligibility

• Relevant medical history: including cardiovascular disease, kidney function, gastrointestinal conditions and mental health

• Contraindications and cautions: the UK SmPCs for GLP-1 receptor agonists used in weight management advise counselling patients on symptoms that may suggest pancreatitis (such as severe, persistent abdominal pain); the UK SmPC for Wegovy (semaglutide) additionally contraindicates use in pregnancy and advises women of childbearing potential on the need for effective contraception.^[13][9] These requirements are medicine-specific and should be confirmed against the relevant UK SmPC for the medicine being considered

• Lifestyle factors: diet, physical activity, sleep and alcohol use are all clinically relevant

• Psychological factors: emotional eating, disordered eating history and mental health conditions affect both treatment choice and likely outcomes

If a service does not ask about these areas before prescribing, that is a meaningful gap in clinical process. A good assessment takes time and requires a trained clinician, not an algorithm alone. If you are uncertain whether an assessment you have received was adequate, your GP is the right person to discuss this with.

Scientific References

1. Obesity: identification, assessment and management (NG238).
2. Tirzepatide for managing overweight and obesity (TA1026).
3. A guide for prescribing medicines to manage overweight and obesity.
4. MHRA approves GLP-1 receptor agonist semaglutide (Wegovy) to reduce risk of serious heart problems in obese or overweight adults.
5. GLP-1 medicines for weight loss and diabetes: what you need to know.
6. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
7. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
8. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
9. Wegovy (semaglutide) – EPAR product information (SmPC).
10. The Yellow Card scheme: guidance for healthcare professionals.
11. Every report counts: support the Yellow Card scheme by reporting suspected side effects.
12. Adverse reactions to drugs – BNF NICE.
13. Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.

Frequently Asked Questions